← Leaderboards
Daniel F Liefwalker
Oregon State University
$1,060,833
Attributed
$1,060,833
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $236.7K · FY2009–22$250K$187.5K$125K$62.5K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$1,060,833 · 2
By mechanism
K01$967,905 · 1
F31$92,928 · 1
Top collaborators
No co-investigators on record.
Most similar at Oregon State University
Same institution · by research overlap
- Robert L Tanguay$34,751,239
- Siva Kumar Kolluri$2,622,711
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingFamilyGenesComplexBiologicalMemberCancer CellGenetic TranscriptionTumorSignal TransductionResponsePathway InteractionsMalignant NeoplasmsCell SurvivalKdm5b GeneClustered Regularly Interspaced Short Palindromic RepeatsClinical TreatmentC-Myc GenesChromatinChromatin ImmunoprecipitationCollaborationsComparativeBromodomainCell Line
Grant awards (9)
KDM5B Mediates Cell Survival in MYC-Dependent T-ALL$182,925
K01 · FY2022 · CA · contact PI
KDM5B Mediates Cell Survival in MYC-Dependent T-ALL$182,925
K01 · FY2021 · CA · contact PI
KDM5B Mediates Cell Survival in MYC-Dependent T-ALL$182,685
K01 · FY2020 · CA · contact PI
KDM5B Mediates Cell Survival in MYC-Dependent T-ALL$54,000
K01 · FY2020 · CA · contact PI
KDM5B Mediates Cell Survival in MYC-Dependent T-ALL$182,685
K01 · FY2019 · CA · contact PI
KDM5B Mediates Cell Survival in MYC-Dependent T-ALL$182,685
K01 · FY2018 · CA · contact PI
The Aryl Hydrocarbon Receptor as a New Therapeutic Target for Cancer$29,968
F31 · FY2012 · CA · contact PI
The Aryl Hydrocarbon Receptor as a New Therapeutic Target for Cancer$31,940
F31 · FY2011 · CA · contact PI
The Aryl Hydrocarbon Receptor as a New Therapeutic Target for Cancer$31,020
F31 · FY2009 · CA · contact PI